Evonetix Granted Patent for Technology Enabling Thermally-controlled DNA Synthesis
EVONETIX LTD (‘Evonetix’), the synthetic biology company bringing semiconductor technology to DNA synthesis, today announced it has been granted patent EP3551331B1 in Europe for its proprietary thermal control technology for DNA synthesis, as well as the design and manufacture of its silicon chips. This patent extends Evonetix’s IP portfolio and is a key step in the Company’s strategy to develop a benchtop DNA synthesis platform, to change how DNA is accessed, made, and used.
Evonetix’s novel approach to parallel DNA synthesis is underpinned by precise, independent, control of temperature at thousands of individual synthesis sites across the surface of a silicon chip. In contrast to conventional approaches, which use acid deprotection to control the synthesis cycle, Evonetix uses thermal control with semiconductor-based arrays. This offers greater accuracy and selectivity to deprotect sequences at the correct point to add the next nucleotide and remove mismatching sequences.
Thermal control of DNA synthesis enables highly parallel synthesis and gives the ability to work through sequences that are hard to synthesise using conventional techniques and to remove errors during the assembly of gene sequences through temperature mediated error removal.
Matthew Hayes, Chief Technology Officer at Evonetix, commented: “There is currently an unmet need in the synthetic biology industry for long, accurate, DNA sequences, and the ability to remove errors during assembly allows researchers to achieve longer strands of DNA, and run applications such as gene synthesis, CRISPR screening, and protein engineering. Securing this patent to cover our core technology adds further strength to our IP portfolio and underlines Evonetix’s position as leaders in our field. Our technology will give researchers the capabilities of service centres in their own lab, accelerating the advancement of synthetic biology and opening new possibilities in this exciting market.”
People In This Post
Companies In This Post
- Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Higher-Risk Myelodysplastic Syndrome Read more
- Merck Animal Health Receives U.S. FDA Approval of Expanded Indication for BRAVECTO Chews for Dogs Read more
- Sharecare Launches VR Program to Improve Well-being of American Workforce Read more
- Cell BioEngines Enters into an Exclusive Worldwide Agreement to Develop and Commercialize Potent Immune Cell States to Cure Cancer Read more
- Nogra Pharma Announces Out-licensing Agreement with Torii Pharmaceutical for Japan for New Chemical Entity Topical Acne Treatment Read more